Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984738 | 1.00 | MAPT (0.54) | MAPTALDH1A1LMNAGPR119HSD11B1 | |
| SCHEMBL2718590 | 1.00 | MAPT (0.54) | MAPTALDH1A1LMNAGPR119HSD11B1 | |
| SCHEMBL31142623 | 0.84 | GPR119 (0.51) | GPR119HSD11B1PARP1HDAC1F13A1 | |
| SCHEMBL30261871 | 0.84 | GPR119 (0.53) | GPR119HSD11B1PARP1HDAC1F13A1 | |
| SCHEMBL1199630 | 0.84 | GPR119 (0.50) | GPR119HSD11B1PARP1HDAC1F13A1 | |
| SCHEMBL23551511 | 0.84 | GPR119 (0.50) | GPR119HSD11B1PARP1HDAC1F13A1 | |
| SCHEMBL15441789 | 0.84 | GPR119 (0.53) | GPR119HSD11B1PARP1HDAC1F13A1 | |
| SCHEMBL1199629 | 0.84 | GPR119 (0.50) | GPR119HSD11B1PARP1HDAC1F13A1 | |
| SCHEMBL1199627 | 0.84 | GPR119 (0.50) | GPR119HSD11B1PARP1HDAC1F13A1 | |
| SCHEMBL25899695 | 0.84 | GPR119 (0.50) | LMNAGPR119HSD11B1PARP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
| EP-4149939-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551850-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2022-12-30 | — | — | CN | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2011-05-19 | — | — | US | disclosed |
| WO-2011054922-A1 | SALTS OF FUSED PYRAZINE COMPOUNDS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES. | GALAPAGOS NV (BE) | 2011-05-12 | — | — | WO | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009135885-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118269-A1 | FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, NLRP3 | MAPT 392/4885ALDH1A1 874/4885LMNA 2810/4885 |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | MAPT 855/4885ALDH1A1 960/4885LMNA 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.